Immunotherapy plus chemo vs. chemo alone for advanced colorectal cancer before surgery
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 75 with colorectal cancer that has not spread to other parts of the body
- Diagnosed as stage II or III colorectal cancer based on imaging scans (CT or MRI)
- Sufficient tumor tissue available for specialized testing (mismatch repair or microsatellite instability)
- No prior chemotherapy or radiation for colorectal cancer
- Good overall health (able to perform daily activities) and normal organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new immunotherapy drug (ivonescimab) to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colon cancer. It compares the combination to chemotherapy alone.
This trial tests whether a stronger chemo combination plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemo alone when given before surgery for locally advanced colon cancer. It aims to shrink the tumor and improve outcomes.
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
This trial tests whether giving chemotherapy before surgery can improve outcomes for people with colon cancer that has grown into nearby tissue or lymph nodes but hasn't spread to other organs. It is for patients whose tumors are mismatch repair proficient (pMMR) or microsatellite stable (MSS).
Hear when a new Locally Advanced Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.